43 search results for: type 2 inflammation

Current systemic therapies have been shown to induce remission in a subset of AD patients
expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

Dermatology
Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.
View more
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
expert video

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Dermatology
Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.
View more
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Dermatology
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
View more
On-Treatment Clinical Remission in Asthma Patients Case Tool
interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

Pulmonology
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.
View more
Impact of Advanced Systemic Therapies on Disease Control in AD
expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

Dermatology
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
View more
Skin Barrier Dysfunction in AD
expert video

Skin Barrier Dysfunction in AD

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.
View more
Dysbiosis, Skin Infections, and Itch
expert video

Dysbiosis, Skin Infections, and Itch

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region